MedTrace Logo

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

NCT00986531 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2011-11-01

No results posted yet for this study

Summary

The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.

Conditions

Interventions

DRUG

AZD8529

2 capsules by mouth for 3 days

DRUG

Placebo to match AZD8529

2 capsules by mouth for 3 days

Sponsors & Collaborators

Principal Investigators

  • Raquel Gur · Hospital of the University of Pennsylvania, Dept of Psychiatry, Neuropsychiatry Section

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00986531 on ClinicalTrials.gov